TABLE 3.
Effect of treatment with (N)-MCT in BALB/c mice infected intranasally with HSV-1
Treatmenta | Mortality
|
MDDb | P value | ||
---|---|---|---|---|---|
No. dead/total no. | % | P value | |||
Placebo | |||||
0.4% CMC | 7/14 | 50 | 8.0 | ||
ACV | |||||
50 mg/kg | 0/15 | 0 | <0.01 | ||
16.7 mg/kg | 0/15 | 0 | <0.01 | ||
5.6 mg/kg | 0/15 | 0 | <0.01 | ||
(N)-MCT | |||||
50 mg/kg | 0/15 | 0 | <0.01 | NSc | |
16.7 mg/kg | 0/15 | 0 | <0.01 | NS | |
5.6 mg/kg | 1/15 | 7 | <0.05 | 20 | 0.05 |
(N)-MCT was prepared in 0.4% CMC and delivered i.p. twice daily in 0.1-ml doses. ACV was prepared in sterile water and given i.p. twice daily in 0.1-ml doses. All animals were treated for 7 days beginning 24 h postinfection.
MDD, mean day of death.
NS, not significant.